132 related articles for article (PubMed ID: 12941340)
1. Indole-based heterocyclic inhibitors of p38alpha MAP kinase: designing a conformationally restricted analogue.
Mavunkel BJ; Chakravarty S; Perumattam JJ; Luedtke GR; Liang X; Lim D; Xu YJ; Laney M; Liu DY; Schreiner GF; Lewicki JA; Dugar S
Bioorg Med Chem Lett; 2003 Sep; 13(18):3087-90. PubMed ID: 12941340
[TBL] [Abstract][Full Text] [Related]
2. KR-003048, a potent, orally active inhibitor of p38 mitogen-activated protein kinase.
Montalban AG; Boman E; Chang CD; Ceide SC; Dahl R; Dalesandro D; Delaet NG; Erb E; Ernst J; Gibbs A; Kahl J; Kessler L; Lundström J; Miller S; Nakanishi H; Roberts E; Saiah E; Sullivan R; Wang Z; Larson CJ
Eur J Pharmacol; 2010 Apr; 632(1-3):93-102. PubMed ID: 20132813
[TBL] [Abstract][Full Text] [Related]
3. Potent inhibitors of the MAP kinase p38.
Henry JR; Rupert KC; Dodd JH; Turchi IJ; Wadsworth SA; Cavender DE; Schafer PH; Siekierka JJ
Bioorg Med Chem Lett; 1998 Dec; 8(23):3335-40. PubMed ID: 9873730
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and SAR of p38alpha MAP kinase inhibitors based on heterobicyclic scaffolds.
Murali Dhar TG; Wrobleski ST; Lin S; Furch JA; Nirschl DS; Fan Y; Todderud G; Pitt S; Doweyko AM; Sack JS; Mathur A; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
Bioorg Med Chem Lett; 2007 Sep; 17(18):5019-24. PubMed ID: 17664068
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a new class of p38 kinase inhibitors.
Dumas J; Sibley R; Riedl B; Monahan MK; Lee W; Lowinger TB; Redman AM; Johnson JS; Kingery-Wood J; Scott WJ; Smith RA; Bobko M; Schoenleber R; Ranges GE; Housley TJ; Bhargava A; Wilhelm SM; Shrikhande A
Bioorg Med Chem Lett; 2000 Sep; 10(18):2047-50. PubMed ID: 10999467
[TBL] [Abstract][Full Text] [Related]
6. p38 MAP kinase inhibitors: many are made, but few are chosen.
Dominguez C; Powers DA; Tamayo N
Curr Opin Drug Discov Devel; 2005 Jul; 8(4):421-30. PubMed ID: 16022178
[TBL] [Abstract][Full Text] [Related]
7. MAPKK-independent activation of p38alpha mediated by TAB1-dependent autophosphorylation of p38alpha.
Ge B; Gram H; Di Padova F; Huang B; New L; Ulevitch RJ; Luo Y; Han J
Science; 2002 Feb; 295(5558):1291-4. PubMed ID: 11847341
[TBL] [Abstract][Full Text] [Related]
8. Recent developments of p38α MAP kinase inhibitors as antiinflammatory agents based on the imidazole scaffolds.
Kong TT; Zhang CM; Liu ZP
Curr Med Chem; 2013; 20(15):1997-2016. PubMed ID: 23317165
[TBL] [Abstract][Full Text] [Related]
9. p38 mitogen-activated protein kinase is activated and linked to TNF-alpha signaling in inflammatory bowel disease.
Waetzig GH; Seegert D; Rosenstiel P; Nikolaus S; Schreiber S
J Immunol; 2002 May; 168(10):5342-51. PubMed ID: 11994493
[TBL] [Abstract][Full Text] [Related]
10. The Pyrazolobenzothiazine Core as a New Chemotype of p38 Alpha Mitogen-Activated Protein Kinase Inhibitors.
Sabatini S; Manfroni G; Barreca ML; Bauer SM; Gargaro M; Cannalire R; Astolfi A; Brea J; Vacca C; Pirro M; Massari S; Tabarrini O; Loza MI; Fallarino F; Laufer SA; Cecchetti V
Chem Biol Drug Des; 2015 Oct; 86(4):531-45. PubMed ID: 25589097
[TBL] [Abstract][Full Text] [Related]
11. Imidazopyrimidines, potent inhibitors of p38 MAP kinase.
Rupert KC; Henry JR; Dodd JH; Wadsworth SA; Cavender DE; Olini GC; Fahmy B; Siekierka JJ
Bioorg Med Chem Lett; 2003 Feb; 13(3):347-50. PubMed ID: 12565927
[TBL] [Abstract][Full Text] [Related]
12. 1-Phenyl-5-pyrazolyl ureas: potent and selective p38 kinase inhibitors.
Dumas J; Hatoum-Mokdad H; Sibley R; Riedl B; Scott WJ; Monahan MK; Lowinger TB; Brennan C; Natero R; Turner T; Johnson JS; Schoenleber R; Bhargava A; Wilhelm SM; Housley TJ; Ranges GE; Shrikhande A
Bioorg Med Chem Lett; 2000 Sep; 10(18):2051-4. PubMed ID: 10999468
[TBL] [Abstract][Full Text] [Related]
13. MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38alpha protein.
Lee MR; Dominguez C
Curr Med Chem; 2005; 12(25):2979-94. PubMed ID: 16378500
[TBL] [Abstract][Full Text] [Related]
14. Role of MAP kinase pathways in mediating IL-6 production in human primary mesangial and proximal tubular cells.
Leonard M; Ryan MP; Watson AJ; Schramek H; Healy E
Kidney Int; 1999 Oct; 56(4):1366-77. PubMed ID: 10504489
[TBL] [Abstract][Full Text] [Related]
15. Selective activation and functional significance of p38alpha mitogen-activated protein kinase in lipopolysaccharide-stimulated neutrophils.
Nick JA; Avdi NJ; Young SK; Lehman LA; McDonald PP; Frasch SC; Billstrom MA; Henson PM; Johnson GL; Worthen GS
J Clin Invest; 1999 Mar; 103(6):851-8. PubMed ID: 10079106
[TBL] [Abstract][Full Text] [Related]
16. Pyridinylimidazole based p38 MAP kinase inhibitors.
Jackson PF; Bullington JL
Curr Top Med Chem; 2002 Sep; 2(9):1011-20. PubMed ID: 12171568
[TBL] [Abstract][Full Text] [Related]
17. N-Phenyl-N-purin-6-yl ureas: the design and synthesis of p38alpha MAP kinase inhibitors.
Wan Z; Boehm JC; Bower MJ; Kassis S; Lee JC; Zhao B; Adams JL
Bioorg Med Chem Lett; 2003 Mar; 13(6):1191-4. PubMed ID: 12643941
[TBL] [Abstract][Full Text] [Related]
18. Pyridazine based inhibitors of p38 MAPK.
McIntyre CJ; Ponticello GS; Liverton NJ; O'Keefe SJ; O'Neill EA; Pang M; Schwartz CD; Claremon DA
Bioorg Med Chem Lett; 2002 Feb; 12(4):689-92. PubMed ID: 11844702
[TBL] [Abstract][Full Text] [Related]
19. Deficiency of the stress kinase p38alpha results in embryonic lethality: characterization of the kinase dependence of stress responses of enzyme-deficient embryonic stem cells.
Allen M; Svensson L; Roach M; Hambor J; McNeish J; Gabel CA
J Exp Med; 2000 Mar; 191(5):859-70. PubMed ID: 10704466
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of potent, orally bioavailable dihydroquinazolinone inhibitors of p38 MAP kinase.
Stelmach JE; Liu L; Patel SB; Pivnichny JV; Scapin G; Singh S; Hop CE; Wang Z; Strauss JR; Cameron PM; Nichols EA; O'Keefe SJ; O'Neill EA; Schmatz DM; Schwartz CD; Thompson CM; Zaller DM; Doherty JB
Bioorg Med Chem Lett; 2003 Jan; 13(2):277-80. PubMed ID: 12482439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
